Tirzepatide

Tirzepatide is a “twincretin” - the first dual GIP/GLP-1 receptor agonist designed to harness the full incretin effect.

The current Mounjaro label includes type 2 diabetes in patients aged 10 years and older, based in part on the 99-participant SURPASS-PEDS trial (PMID:40975112). The Zepbound label covers adult weight reduction and moderate-to-severe OSA in adults with obesity; pediatric safety and effectiveness for Zepbound have not been established. These indications are not interchangeable.

How It Works (Simplified)

Key Research: Willard FS et al. found in receptor and islet experiments that tirzepatide mimicked native GIP signaling at GIPR while showing GLP-1R signaling biased toward cAMP over beta-arrestin recruitment. This does not quantify receptor contributions to clinical weight loss or prove lower GI event rates. PMID:32730231

SURPASS-CVOT — noninferior to dulaglutide, not superior

SURPASS-CVOT is the cardiovascular outcomes trial for tirzepatide, and it was published in the New England Journal of Medicine on 18 December 2025 (PMID:41406444, NCT04255433). It was an active-comparator-controlled, double-blind noninferiority trial: 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease were randomised 1:1 to weekly tirzepatide or dulaglutide 1.5 mg, an agent already shown to reduce cardiovascular events. The modified intention-to-treat population was 6,586 versus 6,579 after 134 exclusions. Mean age was 64.1 years, mean HbA1c 8.4%, and mean diabetes duration 14.7 years.

The primary endpoint — a composite of cardiovascular death, myocardial infarction or stroke — occurred in 801 patients (12.2%) on tirzepatide and 862 (13.1%) on dulaglutide, hazard ratio 0.92 (95.3% CI 0.83 to 1.01). The prespecified noninferiority margin was an upper confidence limit of 1.05, which was met (P=0.003). Superiority required an upper limit below 1.00, and that was not achieved (P=0.09).

The distinction carries the whole result. Tirzepatide was shown not to be meaningfully worse than an agent with proven cardiovascular benefit; it was not shown to be better. Adverse events were broadly similar between groups, with more gastrointestinal events on tirzepatide.

The trial’s registry results were separately posted to ClinicalTrials.gov on 8 July 2026, and add detail the abstract does not carry: all-cause death in 566 versus 669 participants, cardiovascular death in 367 versus 408, and at 36 months HbA1c down 1.66 percentage points versus 0.88 and body weight down 11.6% versus 4.8%. A cardiorenal post hoc analysis was published in JAMA Cardiology in June 2026 (PMID:41903177).

The active-comparator result does not establish superiority to placebo or confer a US cardiovascular risk-reduction indication on Mounjaro or Zepbound. The Zepbound label also warns that delayed gastric emptying can alter oral-drug absorption. It specifically notes reduced efficacy of oral hormonal contraceptives and recommends a non-oral or added barrier method for four weeks after initiation and after each dose escalation; the same issue is in the Mounjaro label. This is a labeled interaction, not a result inferred from a different peptide’s mechanism.

WADA’s 2026 Monitoring Program includes markers of tirzepatide and semaglutide in and out of competition. The program explicitly monitors substances outside the Prohibited List; inclusion is not prohibition.

Important Limitations

• SURPASS-CVOT established noninferiority to dulaglutide, not superiority (P=0.09 for superiority) — it does not show that tirzepatide reduces cardiovascular events more than an existing GLP-1 receptor agonist
• A 2026 meta-analysis of eight studies found no statistically significant MACE reduction for tirzepatide against GLP-1 receptor agonists (HR 0.85, 95% CI 0.70-1.04), with heterogeneity of 90.4% and seven of the eight studies observational
• Gastrointestinal side effects remain common (nausea 12-18%, diarrhea 12-17%), especially during titration
• Thyroid C-cell tumor warning (boxed warning based on rodent studies; clinical relevance in humans uncertain)
• Supply constraints have affected availability since launch; demand continues to exceed supply
• Cost and insurance coverage may limit access for many patients
• Weight regain occurs after discontinuation (SURMOUNT-4 demonstrated this clearly)
• Not studied in combination with other GLP-1 receptor agonists; these should not be combined
• Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2
• Oral hormonal contraceptives: Zepbound and Mounjaro labels identify reduced efficacy after initiation and dose escalation because of delayed gastric emptying.